Search results
Results from the WOW.Com Content Network
List of Antiviral Drugs Antiviral Use Manufacturer Component Type Year approved Abacavir: HIV: ViiV Healthcare: Nucleoside analogue reverse transcriptase inhibitor (NRTI) 1998 Acyclovir (Aciclovir) Herpes Simplex, chickenpox, [2] varicella zoster virus: GSK: guanosine analogue RTI 1981 Adefovir: Hepatitis B [3] Gilead Sciences RTI 2002 , 2003 ...
The COVID-19 pandemic exposed glaring weaknesses in our ability to respond swiftly to novel pathogens. Traditional antiviral drugs, while valuable, are largely specific to single viruses, and thus ...
Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November ...
WHO further recommends in-depth epidemiological investigations to control potential transmission of the resistant virus and prevent future progression. [51] As novel treatments and detection techniques to antiviral resistance are enhanced so can the establishment of strategies to combat the inevitable emergence of antiviral resistance. [52]
The new "FLiRT" COVID-19 variants, including KP.3 and KP.2, are spreading in the United States. Will there be a summer surge? Experts discuss transmission, symptoms, and vaccines.
The research that led to nirmatrelvir began in March 2020, when Pfizer formally launched a project at its Cambridge, Massachusetts site to develop antiviral drugs for treating COVID-19. [15] In July 2020, Pfizer chemists were able to synthesize nirmatrelvir for the first time. [ 15 ]
Obeldesivir (GS-5245, ATV006) is an isobutyric ester prodrug of GS-441524 made by Gilead Sciences that is currently in Phase III trials for the outpatient treatment of COVID-19 in high risk patients. [1] [2] The purpose of the isobutyric ester modification on obeldesivir is to improve the oral bioavailability of the parent nucleoside, GS-441524.
If you recently tested positive for COVID-19, you may be eligible for antiviral treatments to help reduce your infection. Earlier this year, when the omicron variant was steering the pandemic ...